Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 15;7(4):e761.
doi: 10.1212/NXI.0000000000000761. Print 2020 Jul.

COVID-19 and MS disease-modifying therapies

Joseph R Berger  1 , Rachel Brandstadter  2 , Amit Bar-Or  2
Affiliations

COVID-19 and MS disease-modifying therapies

Joseph R Berger et al. Neurol Neuroimmunol Neuroinflamm. .

Abstract

Objective: To address concerns regarding the effect of MS disease-modifying therapies (DMTs) on the expression of coronavirus 2019 (COVID-19).

Methods: Review of the current state of knowledge regarding the viral etiology of COVID-19, mechanisms of injury by SARS-CoV-2 infection, and the effect of individual DMTs on the risk of infection and COVID-19 disease expression.

Results: Although data are limited, MS DMTs do not obviously increase the risk of acquiring symptomatic SARS-CoV-2 infection. The severe morbidity and mortality of SARS-CoV-2 appear to be largely the consequence of an overly robust immune response rather than the consequence of unchecked viral replication. The effects of specific MS DMTs on the immune response that may increase the risk of impaired viral clearance and their potential counterbalancing beneficial effects on the development of COVID-19-associated acute respiratory distress syndrome are reviewed.

Conclusion: Although there is currently insufficient real-world experience to definitively answer the question of the effect of a specific MS DMT on COVID-19, registries presently in nascent form should provide these answers. This review provides an approach to addressing these concerns while the data are being accumulated. Early insights suggest that the risk of infection and associated morbidity of COVID-19 in this population is little different than that of the population at large.

PubMed Disclaimer

References

    1. Ditkoff M. 50 awesome quotes on risk taking [online]. Available at: huffpost.com/entry/50-awesome-quotes-on-risk_b_2078573. Accessed April 22, 2020.
    1. Berger B, Baumgartner A, Rauer S, et al. . Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation. J Neuroimmunol 2015;282:118–122. - PubMed
    1. Faissner S, Hoepner R, Lukas C, Chan A, Gold R, Ellrichmann G. Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment. Ther Adv Neurol Disord 2015;8:233–238. - PMC - PubMed
    1. Gonzalez-Suarez I, Rodriguez de Antonio L, Orviz A, et al. . Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation. Brain Behav 2017;7:e00671. - PMC - PubMed
    1. Sorensen PS, Koch-Henriksen N, Petersen T, Ravnborg M, Oturai A, Sellebjerg F. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol 2014;261:1170–1177. - PubMed

MeSH terms

Substances